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ABSTRACT
Because of its role as an immune checkpoint, levels of soluble programmed 
cell death protein-1 (sPD-1) could be useful as a prognostic biomarker or predictive 
biomarker in cancer patients treated with vaccines. Very low levels of sPD-1 may 
indicate lack of an existing anti-cancer immune response; very high levels may 
indicate an active immune response that is suppressed. In between these extremes, 
a decrease in PD-1 following injections of an anti-cancer vaccine may indicate an 
enhanced immune response that has not been suppressed. Blood samples obtained 
during a randomized trial in patients with metastatic melanoma were tested from 22 
patients treated with a tumor cell vaccine (TCV) and 17 treated with a dendritic cell 
vaccine (DCV). Survival was better in DCV-treated patients. sPD-1 was measured at 
week-0, one week before the first of three weekly subcutaneous injections, and at 
week-4, one week after the third injection. The combination of a very low baseline 
sPD-1, or absence of a very high PD-1 at baseline followed by a decline in sPD-1 at 
week-4, was predictive of surviving three or more years in DCV-treated patients, 
but not TCV-treated. Among DCV-treated patients, these sPD-1 criteria appropriately 
classified 8/10 (80%) of 3-year survivors, and 6/7 (86%) of patients who did not 
survive three years. These preliminary observations suggest that sPD-1 might be a 
useful biomarker for melanoma patients being considered for treatment with this DCV 
vaccine, and/or to predict efficacy after only three injections, but this would have to 
be confirmed in larger studies.
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INTRODUCTION
PD-1 (CD279) was first described by Tasuku 
Honjo and colleagues at Kyoto University in 1992 [1]. 
Dr. Honjo was awarded a Nobel Prize in 2018 for his 
pioneering studies of PD-1, including its expression on 
immune cells, and characterization of its role in regulating 
immune responses via interaction with specific ligands 
(PD-L1 and PD-L2) [2–7]. Because of its role as an 
immune checkpoint, levels of soluble programmed cell 
death protein-1 (sPD-1) could be useful as a prognostic 
biomarker or predictive biomarker in cancer patients 
treated with vaccines because it is upregulated on 
activated lymphocytes by interferon gamma, during a 
Th1 immune response [6, 8–10]. In cancer patients, very 
low levels of sPD-1 may indicate lack of an existing 
anti-cancer immune response while very high levels 
may indicate an active immune response that has been 
suppressed. In between these extremes, a decrease in 
PD-1 following injections of an anti-cancer vaccine may 
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indicate an enhanced immune response that has not been 
suppressed.
The purpose of this study was to determine the 
possible use of sPD-1 as an immune marker in patients 
with metastatic melanoma who were enrolled in a 
randomized phase II trial testing autologous dendritic 
cell vaccines (DCV) and autologous tumor cell vaccines 
(TCV) [11, 12]. In particular, we were looking for a 
surrogate marker that might reflect immune response 
and association with survival in patients treated with 
these vaccines. For both products, the antigen source 
was irradiated autologous cancer cells from short-term 
cell cultures derived from surgically excised autologous 
tumor. We asked the following questions: (1) was 
baseline sPD-1 prognostic for survival in these patients 
with metastatic melanoma, or for either of the two 
treatment-defined cohorts; (2) within each treatment-
defined cohort, was either vaccine efficacious in patients 
with very low sPD-1 levels and/or very high sPD-1 
levels; (3) if there was a change in sPD-1 from week-
0, one week before the first of three weekly vaccine 
injections, to week-4, one week after the third injection, 
was this predictive of survival for all patients or in either 
treatment-defined cohort; and (4) could sPD-1 be used 
to define cohorts that were prognostic or predictive of 
survival.
RESULTS
Summary data
Tables 1 and 2 display the sPD-1 data for all 39 
patients. Table 1 displays the week-0 baseline sPD-1, 
week-4 sPD-1, absolute and percentage changes in sPD-1 
from week-0 baseline to week-4, and actual survival for 
the DCV-treated patients. Table 2 displays similar data 
for TCV-treated patients. In addition, Figure 1 shows the 
changes in sPD-1 levels graphically for each individual 
patient by treatment arm (Figure 1A), and by subcohorts 
based on 3-year survival within each group (Figures 1B 
and 1C). Table 3 shows the median and mean sPD-1 
levels for week-0 and week-4 and changes in the mean 
and median sPD-1 levels for all 39 patients as a group, as 
well as cohorts defined by treatment (DCV or TCV) and/
or survival (greater or less than three years).
Baseline sPD-1 levels were not prognostic for 
survival
The mean sPD-1 level for three healthy controls was 
595 pg/mL, which is in the normal range of 200 to 1200 
pg/mL reported by others [13–21]. For all 39 patients, 
baseline sPD-1 levels ranged from 0 to 511,063 pg/mL 
(Tables 1 and 2) with a mean of 54,566 pg/mL and median 
of 119,845 pg/mL (Table 3). There was no difference in the 
means of baseline sPD-1 for the 17 DCV-treated compared 
to the 22 TCV-treated (Table 3, Figure 2A). There was also 
no difference in the means of baseline sPD-1 for the 16 
patients who survived greater than three years compared 
to the 23 who survived less than three years (Table 3, 
Figure 2A). The most striking variation in Table 3 is the 
high mean week-0 sPD-1 levels for the seven DCV-treated 
patients who survived less than three years. This difference 
is shown graphically in Figure 2B and contrasted to the 
low sPD-1 levels recorded at baseline in the 10 DCV-
treated patients who survived more than three years, and 
in TCV-treated patients. However, because of the wide 
variation in values and the relatively small numbers of 
patients, this great difference in the mean baseline sPD-1 
levels in the 10 DCV-treated patients who survived greater 
than three years was not significantly different compared 
to the sPD-1 levels for the 7 DCV-treated patients who 
survived less than three years (p = 0.131) (Table 3, Figure 
2B). Among TCV-treated patients, the median and mean 
baseline sPD-1 levels were similar for the 16 who survived 
less than three years and for the six who survived greater 
than three years (Table 3, Figure 2B).
Patients were grouped by sPD-1 levels that were 
less than or greater than 1,200 pg/mL, which provided the 
same distribution on either side of the median of 1,509 
for all 39 patients (Tables 1–3). The proportion surviving 
greater than three years was no greater for the 19 patients 
with baseline sPD-1 less than 1,200 pg/mL compared to 
the 20 patients with baseline sPD-1 greater than 1,200 pg/
mL (9/19 versus 7/20, p = 0.523) (Figure 3A). In addition, 
overall survival (OS) was no better for 19 patients with 
baseline sPD-1 less than 1,200 pg/mL compared to 20 
patients with sPD-1 greater than 1,200 pg/mL (median 
OS 33.0 vs 19.9 mos.; 3-yr OS 47% vs 35%, p = 0.453) 
(Figure 3B). Thus, baseline sPD-1 was not a prognostic 
marker for survival for this population of melanoma 
patients.
Changes in sPD-1 levels from week-0 to week-4 
were not predictive of survival
sPD-1 levels decreased in 11 patients and increased 
in 25 (Tables 1, 2, Figure 1). Changes in sPD-1 (increased 
versus decreased) were not predictive of survival as 
shown by dot plot distribution (Figure 4A) and survival 
curves (Figure 4B). In addition, changes in sPD-1 were 
not predictive of survival for either treatment arm (Tables 
1, 2, Figure 1A). Changes in sPD-1 levels were also 
not predictive of survival for the 16 TCV-treated and 7 
DCV-treated patients who survived less than three years 
(Tables 1, 2, Figure 1B), nor for 6 TCV-treated and the 
10 DCV-treated patients who survived more than three 
years (Tables 1, 2, Figure 1C). For each of these cohorts 
the median and mean levels of sPD-1 were unchanged 
between week-0 and week-4 (Table 3). Thus, changes 
in sPD-1 levels were not predictive of survival in either 
treatment arm or any subset.
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Additional analyses by treatment arm suggested 
that a combination of baseline sPD-1 levels and 
changes in sPD-1 levels might be predictive for 
survival
Extremely high baseline sPD-1 levels were 
associated with poor survival in DCV-treated patients, but 
not TCV-treated. The association between baseline sPD-1 
levels and survival of individual patients for all patients 
and by treatment are depicted in Figure 5. There were four 
patients with baseline sPD-1 levels greater than 200,000 
pg/mL (Table 1, 2, Figure 5). Two of these patients were 
DCV-treated; both survived less than 10 months. Two 
were TCV-treated; one survived 21 months, and the other 
survived 5 years. The 5-year survivor was a 69-year-old 
man who entered the study as a recurrent stage 3 patient 
without measurable disease. He received all eight doses of 
TCV but progressed with a small bowel metastasis during 
treatment. This was resected, and during the following 
year he was treated with ipilimumab followed by resection 
of another small bowel recurrence. He received no 
subsequent treatment but remained disease-free the final 
three years of follow-up.
Figure 5 shows that all 15 DCV-treated patients 
with a baseline sPD-1 level of less than 200,000 pg/mL 
survived more than one year, in contrast to the two DCV-
treated patients with a baseline level of greater than 200,000 
pg/mL, neither of whom survived a year (15/15 vs 0/2, p = 
0.0074). Among TCV-treated patients with a baseline sPD-1 
less than 200,000 pg/mL, the proportion surviving one year 
was 14/20 compared to 2/2 for patients with a baseline sPD-
1 greater than 200,000 pg/mL (p = 1.00) (Figure 5).
Relatively low levels of sPD-1 were associated with 
good survival in DCV-treated patients. Among DCV-
treated patients, in the cohort with baseline sPD-1 levels 
less than 500 pg/mL, 5/6 survived more than 3 years 
compared to 5/11 with baseline sPD-1 levels greater than 
500 pg/mL (p = 0.304). No such associations were evident 
for TCV-treated patients. For TCV-treated patients, in the 
cohort with baseline sPD-1 levels less than 500 pg/mL, 2/8 
survived more than 3 years compared to 4/14 with baseline 
sPD-1 levels greater than 500 pg/mL (p = 1.00) (Figure 5). 
However, extremely low levels of sPD-1 were associated 
with good survival in both arms. There were 2/22 patients 
in the TCV-treated group with baseline sPD-1 levels 
less than 100 pg/mL; they survived 30 and 60+ months 
(Table 2). There were 3/17 in the DCV-treated group with 
such low levels, and their survivals were 42, 45, and 60+ 
months (Table 1). Thus, the five patients with the lowest 
baseline sPD-1 levels did relatively well regardless of 
which vaccine they received. None of these patients ever 
received anti-PD-1 or anti-PD-L1 therapy.
Table 1: Autologous dendritic cell vaccine (DCV): soluble programmed death protein-1 (sPD-1) levels before and 
after three weekly injections of DCV and associated survival in patients with metastatic melanoma
Patient Number Week-0 sPD-1 (pg/mL)
Week-4 sPD-1 
(pg/mL)
Change in sPD-1 
(pg/mL) % Change
Survival 
(months)
1 1 198 198 19,700.0% 42.2
2 3 520 517 17,233.3% 44.6
3 75 100 25 34.1% 60+
4 164 0 −164 –100.0% 60+
5 191 532 341 178.5% 19.1
6 372 335 −37 –9.9% 52.9
7 618 650 32 5.2% 25.2
8 897 1,613 716 79.8% 13.0
9 1,733 1,078 −655 –37.8% 53.0
10 2,723 2,226 −497 –18.2% 60+
11 7,645 10,340 2,695 35.3% 60+
12 36,277 48,001 11,724 32.3% 17.6
13 42,393 52,570 10,177 24.0% 60+
14 57,687 19,160 –38,527 −66.8% 18.6
15 62,777 56,841 −5,936 −9.5% 38.6
16 290,060 298,072 8,012 2.8% 7.9
17 511,063 455,212 −55,851 –10.9% 9.6
18 – – – – 60+
sPD-1= soluble PD-1; pg/mL=picogram/milliliter
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A decrease in sPD1 levels was associated with 
longer survival in DCV-treated patients, but not 
TCV-treated
In terms of decreases in sPD-1 levels after three 
injections, there was no difference in the proportion 
of DCV-treated patients compared to TCV-treated 
patients (7/17 vs 7/22, p = 0.74) (Tables 1, 2, Figure 
1A). However, among the patients who had a decline 
in sPD-1 between week-0 and week-4, 5/7 DCV-treated 
patients survived three years (Table 1), compared to 
0/7 TCV-treated patients (p = 0.021) (Table 2). This 
observation combined with the associations of survival 
with very low and very high baseline sPD-1 levels led 
to the creation of two cohorts defined by a combination 
of baseline sPD-1 levels and changes in sPD-1 between 
week-0 and week-4.
Classification using a combination of baseline 
sPD-1 and change in sPD-1 was predictive of 
survival for DCV-treated patients
Patients were classified by a combination of 
baseline sPD-1 levels and change in sPD-1 levels between 
week-0 and week-4. Specifically, one cohort (sPD-1 
low/decreased) was defined by a baseline sPD-1 of less 
than 100 pg/mL, or less than 200,000 pg/mL but with 
a decrease in sPD-1 between week-0 and week-4. The 
second cohort (sPD-1 high/increased) was defined by 
a baseline sPD-1 of greater than 200,000 pg/mL, or an 
Table 2: Autologous tumor cell vaccine (TCV): soluble programmed death protein-1 (sPD-1) levels before and after 
three weekly injections of TCV and associated survival in patients with metastatic melanoma
Patient Number Week-0 sPD-1 (pg/mL)
Week-4 sPD-1 
(pg/mL)
Change in sPD-1 
(pg/mL) % change
Survival 
(months)
1 15 462 447 96.8% 60+
2 26 247 221 89.5% 30.3
3 183 230 47 20.4% 4.0
4 193 388 195 50.3% 9.3
5 233 694 461 66.4% 60+
6 238 481 243 50.5% 13.2
7 364 259 -105 −40.5% 33.7
8 446 234 -212 −90.6% 32.2
9 877 1,591 714 44.9% 3.9
10 1,075 1,584 509 32.1% 60+
11 1,152 1,488 336 22.6% 60+
12 1,509 745 −764 -102.6% 9.0
13 2,201 2,238 37 1.7% 16.9
14 8,121 5,710 -2,411 95.3% 9.9
15 16,277 29,276 12,999 −42.2% 14.6
16 32,287 41,123 8,836 44.4% 21.7
17 35,637 43,826 8,189 21.5% 2.5
18 43,095 50,939 7,844 18.7% 60+
19 82,755 58,223 -24,532 15.4% 19.9
20 150,588 118,159 -32,429 -27.4% 32.3
21 343,919 389,327 45,408 11.7% 60+
22 392,201 364,014 -28,187 −7.7% 21.1
23 – – – – 0.7
24 – – – – 1.1
sPD-1 = soluble PD-1; pg/mL = picogram/milliliter.
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increase in sPD-1 between week-0 and week-4. Figure 6 
shows the survival of DCV-treated patients individually 
by dot plot (Figure 6A) and collectively by survival curves 
(Figure 6B), based on these classifications. Those in the 
sPD-1 low/decreased group had better survival. Figure 
6A shows that 9/17 (52.9%, 95% CI 29.2% to 76.6%) 
of DCV-treated patients had a baseline sPD-1 level 
< 100 pg/mL, or a week-0 level between 100 pg/mL and 
200,000 pg/mL and a subsequent decrease in sPD-1 levels; 
their median survival was more than four years with 8/9 
surviving beyond three years. In contrast, Figure 6A also 
shows that the 8/17 DCV-treated patients in the sPD-1 
high/increased group had a median survival of less than 
two years, and only 2/8 survived beyond three years (p 
= 0.0152). Thus, among the 17 DCV-treated patients, the 
classification using a combination of baseline sPD-1 and 
changes in sPD1 correctly classified 8/10 (80%) of 3-year 
survivors, and 6/7 (86%) of patients who survived less 
than three years.
The one false positive patient who survived less 
than 3-years was a 56-year-old female with measurable 
metastatic disease and elevated lactic dehydrogenase at the 
time of vaccine treatment. Her sPD-1 was 57,587 pg/mL at 
baseline and decreased to 19,160 at week-4 (patient #14, 
Table 1). She received all eight DCV doses, but was found 
to have progressive disease prior to receiving the last dose. 
She subsequently was treated with a combination of low-
doses of GM-CSF, interleukin-2 and interferon alpha, then 
a combination of temozolomide, docetaxel, thalidomide, 
and sorafenib, and finally albumin-bound paclitaxel.
There were two false negative cases, that is, patients 
for whom the sPD-1 model predicted survival less than 
three years, but both were still alive five years later. The 
first was a 46-year-old male who was disease-free after 
resection of recurrent stage III disease. His sPD-1 was 
42,393 pg/mL at baseline and increased to 52,570 pg/mL 
at week-4 (patient #13, Table 2). Two years after finishing 
the eight vaccine doses, he had a solitary lung metastasis 
that was treated with localized intensity modulated high-
dose radiation. He remained disease-free thereafter. The 
other false negative was a 55-year-old male who had 
experienced local recurrence of ocular melanoma and 
liver metastases prior to receiving the vaccine, but had no 
measurable disease at the time of enrollment. His baseline 
sPD-1 was 7,645 pg/mL and increased to 10,340 pg/mL at 
week-4 (patient #11, Table 2). He received all eight doses 
but developed new liver metastases about 10 months after 
completing the vaccine. He subsequently responded well 
Figure 1: Changes in sPD-1 between week-0 and week-4 for individual patients. (A) shows all 39 patients by treatment arm - 
dendritic cell vaccine (DCV) or tumor cell vaccine (TCV); (B) shows the 23 patients who survived less than three years by treatment arm 
(DCV or TCV); and (C) shows the 16 patients who survived more than three years by treatment arm (DCV or TCV).
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to high-dose interleukin-2 but progressed, then responded 
well to anti-PD-1 therapy, but again progressed, and was 
receiving ipilimumab for progressive disease at the time of 
5-year follow-up. He was the only patient among the 39 to 
have received anti-PD-1 therapy during the course of the 
trial and follow-up.
At first glance it appeared that perhaps TCV-treated 
patients were more likely to survive three years if their 
sPD-1 level increased between week-0 and week-4 (5/14) 
as opposed to decreasing (1/8), but this difference was not 
significant (p = 0.351) (Table 3, Figures 1B, 1C). Figure 
7 shows the survival of TCV-treated patients, individually 
by dot plot (Figure 7A) and collectively by survival 
curves (Figure 7B) based on the same criteria used to 
classify DCV-treated patients. There were 8/22 TCV-
treated patients in the sPD-1 low/decreased cohort. Their 
probability of surviving more than three years was no 
different than for those TCV-treated who were classified as 
sPD-1 high/increased (Figure 7). In TCV- treated patients, 
the sPD-1 criteria correctly classified only 1/6 (17%) of 
Table 3: Soluble programmed death protein-1 (sPD-1) levels in metastatic melanoma patients enrolled in a randomized 
trial
Population Number of Patients
Median 
sPD-1 (pg/
mL)
Mean sPD-
1 (pg/mL)
St Dev 
sPD-1 (pg/
mL)
Change Mean 
Wk-0 to Wk-4 
(pg/mL)
Change Median Wk-0 
to wk-4 (pg/mL)
All Wk-0 N = 39 1,509 54,566 119,845 −1779 +82
All Wk-4 N = 39 1,591 52,787 115,284 (−3.3%) (+5.4%)
> 3 yr survival
Wk-0 n = 16 1,114 31,711 85,580 +3,833 +170
Wk-4 n = 16 1,283 35,544 96,663 (+12.1%) (+15.2%)
< 3 yr survival
Wk-0 n = 23 2,201 70,465 138,459 −5,683 +37
Wk-4 n = 23 2,238 64,782 127,312 (−8.1%) (+1.7%)
Treatment arm
TCV Wk-0 n = 22 1,331 50,609 109,063 −98 +257
TCV Wk-4 n = 22 1,588 50,511 109,634 (−0.2%) (+19.3%)
DCV Wk-0 n = 17 1,733 59,687 135,833 –3,955 −120
DCV Wk-4 n = 17 1,613 55,732 125,510 (−6.6%) (−6.9%)
Treatment arm and survival
TCV OS < 3 yrs
Wk-0 n = 16 1,855 45,244 101,076 –3,572 +60
Wk-4 n = 16 1,915 41,672 91,864 (–7.9%) (+3.2%)
TCV OS > 3 yrs
Wk-0 n = 6 1,114 64,915 137,736 +9,167 +423
Wk-4 n = 6 1,536 74,082 155,722 (+14.1%) (+37.9%)
DCV OS < 3 yrs
Wk-0 n = 7 36,277 128,113 197,937 –10,508 –17,117
Wk-4 n = 7 19,160 117,606 183,449 (–8.2%) (–47.2%)
DCV OS > 3 yrs
Wk-0 n = 10 1,053 11,788 22,155 +632 –254
Wk-4 n = 10 799 12,421 22,522 (+5.4%) (–24.1%)
sPD-1= soluble programmed death protein-1. Data shown is for all 39 patients
(All) and for two treatment-defined cohorts: TCV = autologous tumor cell vaccine (TCV) (n = 22); DCV = autologous 
dendritic cell vaccine (DCV) (n = 17). OS = overall survival. Subcohorts were defined by treatment arm and survival 
greater than (>) or less than (<) three years (3 yrs). Grouped sPD-1 levels were measured at baseline, one week before 
starting vaccine therapy (wk-0), and four weeks later (wk-4), after the first three vaccine injections.
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3-year survivors and 10/16 (62%) of patients who survived 
less than three years.
DISCUSSION
The most interesting aspect of this analysis was 
the finding that in DCV-treated patients, the “sPD-1 low/
decreased” criteria defined by a baseline sPD-1 level less 
than100 pg/mL or a baseline level less than 200,000 pg/mL 
with a subsequent decrease in sPD-1 after three weekly 
vaccinations, correctly classified 80% of 3-year survivors 
and 86% of patients who survived less than three years. 
Similar associations were not seen in TCV-treated patients. 
In addition to the predictive value of very low or very 
high baseline sPD-1 levels in DCV-treated patients, in the 
intermediate range between 100 pg/mL and 200,000 pg/mL, 
a decrease in sPD-1 levels following vaccination was 
associated with better survival among DCV-treated patients, 
but not TCV-treated patients. This is additional evidence 
that the immunological effects of these two patient-
specific vaccines are quite different, and likely explain the 
differences in survival between the treatment arms [12].
Figure 2: Mean levels of baseline sPD-1 in various cohorts. (A) shows there was no difference in sPD-1 levels (Mann–Whitney 
U Test) by survival less than three years versus greater than three years, or DCV versus TCV treatment arm. (B) shows a trend toward 
higher sPD-1 levels in DCV-treated patients who survived less than three years compared to those who survived more than three years (p 
= 0.131 Mann–Whitney U-Test) This was not observed in the TCV-treated patients (p = 0.857 Mann–Whitney U-Test). sPD-1= soluble 
programmed cell death protein-1, DCV=dendritic cell vaccine, TCV=tumor cell vaccine. Data are presented as mean ± SD.
Figure 3: Survival based on whether baseline sPD-1 level was above or below 1,200 pg/mL. (A) dot plot shows the 
distribution of survival for the 19 patients who had a baseline sPD-1 level less than 1,200 pg/mL, and for the 20 patients who had a baseline 
sPD-1 level greater than 1,200 pg/mL. The proportions who survived more than three years, 9/19 vs 7/20, did not differ (p = 0.523, Fisher 
Exact Test). (B) shows actual survival curves (all patients followed to death or five years with none lost to follow-up). There was no 
difference between the curves (p = 0.453, Mantel-Haenszel log rank-test). sPD-1 = soluble programmed cell death protein-1.
Oncotarget5366www.oncotarget.com
Figure 4: Survival by whether sPD-1 increased or decreased between week-0 and week-4. (A) shows distribution of survival 
with mean and standard deviation bars for the 14 patients whose sPD-1 decreased and for the 25 patients whose sPD-1 increased between 
week-0 and week-4. The proportions who survived more than three years, 5/14 vs 11/25, did not differ (p = 0.740, Fisher Exact Test). 
(B) shows the actual survival curves (all patients followed to death or five years with none lost to follow-up). There was no difference 
between the curves (p = 0.624, Mantel-Haenszel log rank-test). sPD-1 = soluble programmed cell death protein-1.
Figure 5: Survival distribution for all patients by treatment. The 39 patients are grouped by four different ranges of baseline 
sPD-1 levels. There was no difference in survival based on week-0 baseline sPD-1 ranges. Medians for all patients in each sPD-1 range 
are shown by black bar. Survivals for individual patients are shown for each of the 17 DCV-treated (blue) and each of the 22 TCV-treated 
patients (red). For DCV-treated patients who had baseline sPD-1 levels less than 200,000 pg/mL, 15/15 survived more than one year 
compared to 0/2 who had baseline sPD-1 levels greater than 200,000 pg/mL (p = 0.0074, Fisher Exact Test). For TCV-treated patients who 
had baseline sPD-1 levels less than 200,000 pg/mL, 14/20 survived more than one year compared to 2/2 who had sPD-1 levels greater than 
200,000 at baseline (p = 1.00 Fisher Exact Test). For DCV-treated patients who had baseline sPD-1 levels less than 500 pg/mL, 6/6 survived 
more than one year compared to 9/11 DCV-treated patients who had baseline sPD-1 levels greater than 500 pg/mL (p = 0.515, Fisher Exact 
Test). For TCV-treated patients who had baseline sPD-1 levels less than 500 pg/mL, 6/8 survived more than one year compared to 10/14 
who had sPD-1 levels greater than 200,000 pg/mL at baseline (p = 1.00 Fisher Exact Test). sPD-1= soluble programmed death protein-1.
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The major strength of this study is that paired blood 
samples to measure sPD-1 were obtained from patients 
enrolled in a randomized trial with long-term survival 
data for correlations, with all patients followed until death 
or up to five years with no patients lost to follow-up. 
Weaknesses of the study are the relatively small number 
of patients sampled, and not having paired samples for 
100% of patients enrolled in the trial.
Figure 7: sPD-1 and survival of metastatic melanoma patients treated with autologous tumor cell vaccine. Survival is 
shown by individual patients displaying mean with standard deviation (A), and actual survival curves (B) for two cohorts of TCV-treated 
patients. All patients were followed to death or for five years with none lost to follow up. The two cohorts were defined by baseline levels 
of sPD-1 and changes in sPD-1 levels between week-0 and week-4. In TCV-treated patients, having sPD-1 level less than 100 pg/mL at 
baseline, or sPD-1 less than 200,000 pg/mL and a decrease in sPD-1 from week 0 to week 4 (sPD-1 low/decreased), was not predictive 
of longer survival compared to sPD-1 level of greater than 200,000 pg/mL or greater than 100 pg/mL and an increase in sPD-1 between 
week-0 and week-4 (sPD-1 high/increased). (A) dot plot: survival greater than 3 years in 5/14 vs 1/8 (p = 0.351 Fisher Exact Test). (B) 
survival curves: median OS 30.3 vs 16.9 mos (p = 0.791, Mantel-Haenszel log rank test). sPD-1=soluble programmed death protein-1, 
TCV=tumor cell vaccine.
Figure 6: sPD-1 levels and survival of metastatic melanoma patients treated with autologous dendritic cell vaccine. 
Survival is shown by individual patients displaying mean with standard deviation (A) and actual survival curves (B) for two cohorts of 
DCV-treated patients. All patients were followed to death or for five years with none lost to follow-up. The two cohorts were defined by 
baseline levels of sPD-1 and changes in sPD-1 levels between week-0 and week-4. In DCV-treated patients, having sPD-1 level less than 
100 pg/mL at baseline, or sPD-1 less than 200,000 pg/mL and a decrease in sPD-1 from week-0 to week-4 (sPD-1 low/decreased), was 
predictive of longer survival compared to sPD-1 level of greater than 200,000 pg/mL or greater than100 pg/mL and an increase in sPD-1 
between week-0 and week-4 (sPD-1 high/increased). (A) dot plot: survival greater than 3 years in 8/9 vs 2/8 (p = 0.0152, Fisher Exact 
Test). (B) survival curves: median OS 48.8 vs 17.6 months (p = 0.182, Mantel-Haenszel log rank test). sPD-1=soluble programmed death 
protein-1, DCV=dendritic cell vaccine.
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This preliminary data suggests that baseline sPD-1 
levels could be useful as a prognostic marker to exclude 
patients with little chance of benefitting from treatment 
with DCV, and that combining baseline sPD-1 levels 
with changes in sPD-1 levels after vaccination could be 
useful as a predictive marker of survival; and, therefore 
possibly could be a surrogate marker for survival in trials 
of metastatic melanoma patients treated with DCV. Having 
a surrogate marker for survival would be extremely useful 
for rapidly predicting benefit from DCV therapy in the 
context of a clinical trial. Excluding patients with very 
high baseline sPD-1 levels might be useful to enrich for a 
patient-population that has a better chance of benefitting 
from such a vaccine. However, because of the nature of 
this analysis and the small numbers of patients analyzed, 
the findings must be interpreted as preliminary and 
hypothesis-generating rather than definitive, and should be 
explored prospectively in many more patients. It is unclear 
whether this sPD-1 classification would be useful with any 
other vaccine or in other tumor types.
The findings in this study did not support baseline 
sPD-1 levels as a prognostic marker for this population 
of metastatic melanoma patients who enrolled in a 
clinical trial testing patient-specific autologous cell-based 
vaccines. For all 39 patients, there was no difference in 
mean or median levels at baseline or four weeks later 
after the first three vaccine injections (Figure 1, Table 
3). However, the associations between sPD-1 levels and 
survival were quite different in DCV-treated patients 
compared to TCV-treated patients, even though samples 
were not analyzed for the two TCV-treated patients who 
had the worst outcome among all patients, nor a DCV-
treated patients who was one of the 12 patients in the 
randomized clinical trial who survived five years [12]. 
Being classified as sPD-1 low/decreased appeared to have 
predictive significance for patients treated with DCV, but 
not TCV. The two DCV-treated patients with the highest 
levels of sPD-1 at baseline had relatively poor survival.
There have been a few other reports examining sPD-
1 levels in various cancers with no consistent prognostic 
or predictive patterns [16–21]. In one study, higher 
levels of sPD-1 were associated with longer progression-
free survival and OS in 38 patients with non-small cell 
lung cancer who were being treated with erlotinib, an 
inhibitor of mutated epidermal growth factor receptor 
[17]. Among patients with hepatitis B virus, those who 
had an elevated sPD-1, had a higher risk of developing 
hepatocellular cancer [18]. Among 120 patients with 
hepatocellular cancer, those who had higher sPD-1 levels 
had a worse prognosis [19]. In 41 patients with advanced 
pancreatic cancer, sPD-1 levels were not correlated with 
outcome [21]. In that study, levels of sPD-1 and sPD-L1 
were closely correlated and elevated in association with 
an elevated c-reactive protein, suggestive of systemic 
inflammation, and tumor infiltration with T cells, which 
was consistent with an active anti-tumor immune response 
that was being blunted. In that trial, the median sPD-1 level 
was only 117 pg/mL with a range from 40 to 26,000 pg/
mL using an ELISA with chemoluscent detection. While 
sPD-1 was detectable in the serum of all patients analyzed, 
sPD-L1 was below the lower limit of detection in 15/41.
Does the data from the vaccine trial make sense 
immunologically? It may in terms of concepts of “immune 
deserts” and checkpoint inhibition of activated immune 
responses [22, 23]. Patients with no immune response 
would be expected to have very low levels of sPD-1 
and might benefit from an effective vaccine given alone, 
concurrently with, or preceding treatment with anti-PD-1 
or anti-PD-L1. All three DCV-treated patients with a 
baseline sPD-1 less than 100 pg/mL survived at least 3.5 
years, and none received treatment with anti-PD-1 or anti-
PD-L1. Patients with a very high sPD-1 level might not 
benefit from induction of additional immune responses 
to more antigens, or increased responses to recognized 
antigens, but might benefit from anti-PD-1 or anti-PD-L1 
therapy to unleash the previously suppressed immune 
responses. Those patients with levels in between the 
extremes likely would benefit from the combination of a 
vaccine with anti-checkpoint inhibitor therapy [23–25]. 
There was much better survival in DCV-treated patients, 
which we believe is because the DCV is more effective 
than the TCV as a therapeutic vaccine approach in cancer 
patients, because of the ex vivo loading of the cellular 
antigens onto dendritic cells [11, 12, 26, 27].
The data may also make sense immunologically 
because of the potential association between sPD-1 and 
suppression of immune responses. We believe the levels 
of sPD-1 and changes in sPD-1 are a reflection of Th1 
immune responses and their suppression by the PD-1/PD-
L1 axis. A recently induced or augmented immune response 
may be suppressed by increases in PD-1 expression by T 
lymphocytes that may result in increases in sPD-1. A decrease 
in sPD-1 or a lack of increase of sPD-1 following DCV may 
be indicative of lack of inhibition of a new effective immune 
response via the PD-1/PD-L1 regulatory axis.
MATERIALS AND METHODS
Patients and blood samples
Blood samples were obtained from metastatic 
melanoma patients who were enrolled in a randomized 
phase II trial that tested an autologous tumor cell vaccine 
(TCV) and an autologous dendritic cell vaccine (DCV) 
(NCT00948480) [11, 12]. The trial was conducted per 
the doctrine of Helsinki and all subjects gave written 
informed consent to participate. The details regarding the 
vaccine products and patient outcomes were previously 
published [11, 12]. Briefly, TCV consisted of irradiated 
self-renewing cancer cells, and DCV consisted of 
autologous dendritic cells loaded with antigens from self-
renewing autologous cancer cells. Such cancer cells have 
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characteristics of tumor initiating cells including cancer 
stem cells and progenitor cells [28, 29]. DC were derived 
from peripheral blood mononuclear cells obtained during 
a leukapheresis procedure. Both cellular vaccines were 
suspended in granulocyte-macrophage colony stimulating 
factor (GM-CSF) for subcutaneous injections that were 
planned for weeks 1, 2, 3, 8, 12, 16, 20, and 24.
The eligibility criteria, patient characteristics, early 
survival and long-term survival outcomes for the patients 
enrolled in the randomized trial have been published [11, 
12]. Basically patients had to have stage 4 or recurrent 
stage 3 melanoma, had undergone resection of one or 
more lesions from which a short-term cell line had been 
established, had a Karnofsky performance status of 70 or 
greater at the time of randomization, and were referred 
by their managing physician for randomization to TCV 
or DCV. As previously reported, the original plan was to 
enroll 200 patients, but enrollment was discontinued early 
at a time when 42 patients had been randomized [11]. As 
recently published, long-term follow up of the randomized 
trial confirmed that DCV was associated with longer 
median survival (43.4 vs 20.5 months), better actual 
survival at three years (61% vs 25%, p = 0.018), and a 
70% reduction in the risk of death (p = 0.0053) [12].
As a component of the trial, patients had blood 
samples collected one week before starting the vaccine 
injections, and one week after the third weekly injection. 
The focus of this report are the patients for whom blood 
samples were available from both week-0, one week prior 
to the first injection, and week-4, one week following the 
third injection. Paired samples were available for 39 of the 
42 patients. The three patients for whom blood samples 
were missing were two TCV-treated patients who did not 
have week-4 blood samples collected because of rapidly 
progressive disease, and one DCV-treated patient who 
survived more than five years, but rescinded permission 
to test his blood. Even without the survival data from those 
three patients, the proportion surviving three years was 
still greater among DCV-treated patients than TCV-treated 
patients (10/17 versus 6/22, p = 0.047, Fisher Exact Test).
Soluble PD-1 levels
Paired cryopreserved serum samples from week-
0 and week-4 from each patient were analyzed using a 
quantitative, multiplex enzyme-linked immunosorbent 
assay per good laboratory practice (GLP) standards 
(Raybiotech, Inc., Norcross, GA). Results for sPD-1 were 
reported in picograms/milliliter (pg/mL).
Statistics
Proportions were compared using the Fisher exact 
test. Because of the broad data distribution, grouped sPD-
1 levels were compared by the non-parametric Mann–
Whitney U test. Paired comparisons of week-0 versus 
week-4 sPD-1 levels were made by the Wilcoxon signed-
rank test. Differences in survival curves were compared 
using the Mantel-Haenszel log-rank test. For all tests, the 
significance level was 0.05 and hypothesis tests were two-
tailed.
CONCLUSIONS
The combination of sPD-1 levels at baseline and 
change in sPD-1 levels following three weekly vaccines, 
appeared to predict long-term survival in patients with 
metastatic melanoma who were treated with autologous 
DCV. However, the retrospective analysis and small 
patient numbers mean that this is only hypothesis-
generating and requires confirmation in larger trials.
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